Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Symbol: NASDAQ:IMMU
CUSIP: 45290710
Web: www.immunomedics.com

Capitalization:

Market Cap: $830.8 million
Outstanding Shares: 109,604,000

Average Prices:

50 Day Moving Avg: $6.20
200 Day Moving Avg: $4.85
52 Week Range: $1.95 - $7.70

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -15.47
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $3.38 million
Price / Sales: 245.80
Book Value: ($1.20) per share
Price / Book: -6.32

Profitability:

EBIDTA: ($63,800,000.00)
Net Margins: -2,385.59%
Return on Assets: -116.00%

Debt:

Debt-to-Equity Ratio: -1.30%
Current Ratio: 1.69%
Quick Ratio: 1.67%

Misc:

Average Volume: 3.38 million shs.
Beta: 1.68
Short Ratio: 6.03

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Thursday, February, 9th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The firm earned $0.38 million during the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

2 equities research analysts have issued 12 month price objectives for Immunomedics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Immunomedics' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 28,632,680 shares, an increase of 12.4% from the April 13th total of 25,462,665 shares. Based on an average daily trading volume, of 2,159,954 shares, the days-to-cover ratio is currently 13.3 days. Currently, 28.8% of the shares of the company are short sold.

Who are some of Immunomedics' key competitors?

Some companies that are related to Immunomedics include Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Array Biopharma (ARRY), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Repligen (RGEN), Loxo Oncology (LOXO), Blueprint Medicines Corp (BPMC), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), Dermira (DERM), Coherus Biosciences (CHRS), Insmed Incorporated (INSM), Xencor (XNCR), Acceleron Pharma (XLRN), Epizyme (EPZM) and Insys Therapeutics (INSY).

Who owns Immunomedics stock?

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include VENBIO SELECT ADVISOR LLC (9.90%), VENBIO SELECT ADVISOR LLC (9.90%), Vanguard Group Inc. (4.16%), State Street Corp (3.21%), Redmile Group LLC (3.08%) and FMR LLC (1.44%). Company insiders that own Immunomedics stock include Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Schwab Charles Investment Management Inc., Morgan Stanley, Wells Fargo & Company MN, ProShare Advisors LLC, TIAA CREF Investment Management LLC, Alliancebernstein L.P. and IFP Advisors Inc. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, State Street Corp, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Vanguard Group Inc., FMR LLC, Perceptive Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immunomedics stock cost?

One share of Immunomedics stock can currently be purchased for approximately $7.58.

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$9.00 (18.73% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
5/6/2017	Jefferies Group LLC	Set Price Target	Buy	$9.00	High
5/5/2017	Wells Fargo & Co	Upgrade	Market Perform -> Outperform		High
7/29/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform		N/A

(Data available from 5/23/2015 forward)

Earnings History for Immunomedics (NASDAQ:IMMU)

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Earnings History by Quarter for Immunomedics (NASDAQ:IMMU)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/9/2017	Q2 2017	($0.13)	($0.16)	$0.70 million	$0.38 million	View	Listen
11/2/2016	Q117	($0.14)	($0.17)	$0.70 million	$0.74 million	View	N/A
8/17/2016	Q416	($0.11)	($0.17)	$0.90 million	$0.93 million	View	Listen
5/4/2016	Q3	($0.13)	($0.15)	$0.70 million	$0.90 million	View	N/A
2/3/2016	Q216	($0.14)	($0.15)	$1.40 million	$0.67 million	View	N/A
11/4/2015	Q116	($0.14)	($0.16)	$1.23 million	$0.73 million	View	N/A
8/19/2015	Q415	($0.13)	($0.13)	$1.13 million	$2.40 million	View	Listen
5/6/2015	Q3 2015	($0.13)	($0.13)	$1.07 million	$1.18 million	View	N/A
2/4/2015	Q215	($0.13)	($0.12)	$1.73 million	$1.00 million	View	N/A
11/5/2014	Q1 2015	($0.12)	($0.13)	$1.18 million	$1.07 million	View	N/A
8/25/2014	Q414	($0.13)	($0.13)	$1.20 million	$1.20 million	View	N/A
5/7/2014	Q3 2014	($0.12)	$0.02	$1.13 million	$1.15 million	View	N/A
2/10/2014	Q214	($0.10)	($0.10)	$1.20 million	$1.20 million	View	N/A
8/22/2013	Q4 2013	($0.12)	($0.09)	$0.81 million	$1.40 million	View	N/A
5/8/2013	Q3 2013	($0.10)	$0.11	$0.97 million	$1.70 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Immunomedics (NASDAQ:IMMU)

2017 EPS Consensus Estimate: ($0.53)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.12)	($0.12)	($0.12)
Q2 2017	1	($0.15)	($0.15)	($0.15)
Q3 2017	1	($0.15)	($0.15)	($0.15)
Q4 2017	1	($0.11)	($0.11)	($0.11)

(Data provided by Zacks Investment Research)

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)

Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 48.83%

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/24/2016	Don C Stark	Director	Sell	9,900	$2.97	$29,403.00
8/23/2016	Mary E Paetzold	Director	Sell	15,000	$2.98	$44,700.00
6/13/2016	Cynthia L Goldenberg	CEO	Sell	371,990	$3.03	$1,127,129.70
6/8/2016	Cynthia L Goldenberg	CEO	Sell	41,441	$3.62	$150,016.42
6/8/2016	David M Goldenberg	Chairman	Sell	353,010	$3.88	$1,369,678.80
6/7/2016	Cynthia L Goldenberg	CEO	Sell	4,600	$4.01	$18,446.00
6/7/2016	David M Goldenberg	Chairman	Sell	12,300	$3.98	$48,954.00
6/6/2016	Cynthia L Goldenberg	CEO	Sell	63,959	$4.09	$261,592.31
6/6/2016	David M Goldenberg	Chairman	Sell	110,322	$4.09	$451,216.98
6/15/2015	David M Goldenberg	Chairman	Sell	210,991	$4.08	$860,843.28
6/12/2015	Brian A Markison	Director	Sell	5,564	$4.22	$23,480.08
6/12/2015	David M Goldenberg	Chairman	Sell	359,653	$4.32	$1,553,700.96
6/9/2015	Mary E Paetzold	Director	Sell	4,677	$4.60	$21,514.20
6/5/2015	Don C Stark	Director	Sell	5,732	$4.14	$23,730.48
12/11/2014	Mary E Paetzold	Director	Sell	10,000	$4.71	$47,100.00
12/9/2014	Don C Stark	Director	Sell	5,500	$4.51	$24,805.00
9/13/2013	Don Stark	Director	Sell	10,000	$6.08	$60,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Immunomedics (NASDAQ:IMMU) Latest Headlines for Immunomedics (NASDAQ:IMMU)

Source:

Date	Headline
	Company Spotlight: Immunomedics www.rttnews.com - May 12 at 6:36 PM
	Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT finance.yahoo.com - May 12 at 2:04 AM
	Immunomedics, Inc. (IMMU) Short Interest Up 12.4% in April www.americanbankingnews.com - May 11 at 7:34 AM
	BRIEF-Immunomedics Q3 loss per share $0.55 www.reuters.com - May 10 at 6:22 PM
	Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments finance.yahoo.com - May 10 at 6:22 PM
	Immunomedics reports 3Q loss finance.yahoo.com - May 10 at 6:22 PM
	Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results finance.yahoo.com - May 10 at 1:20 PM
	Equities Analysts Issue Forecasts for Immunomedics, Inc.'s FY2017 Earnings (IMMU) www.americanbankingnews.com - May 10 at 9:58 AM
	Immunomedics (IMMU) Earns Daily Coverage Optimism Score of 0.19 www.americanbankingnews.com - May 9 at 12:50 AM
	Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017 finance.yahoo.com - May 8 at 5:33 PM
	Biotech Stocks Under Scanner -- Rexahn Pharma, Peregrine Pharma, Immunomedics, and Protalix BioTherapeutics www.bizjournals.com - May 8 at 7:18 AM
	Immunomedics Breaks Out, But Will It Last? finance.yahoo.com - May 8 at 7:18 AM
	Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated? finance.yahoo.com - May 6 at 9:50 AM
	Immunomedics (IMMU) Receives Daily Media Sentiment Score of 0.22 www.americanbankingnews.com - May 5 at 11:22 PM
	BRIEF-Immunomedics announces private placement offering www.reuters.com - May 5 at 10:54 PM
	Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value finance.yahoo.com - May 5 at 10:54 PM
	BRIEF-Immunomedics announces private placement offering - Reuters www.reuters.com - May 5 at 5:52 PM
	Why Immunomedics, Inc. Rocketed Today - Motley Fool www.fool.com - May 5 at 5:52 PM
	Why Immunomedics, MercadoLibre, and Pearson Jumped Today finance.yahoo.com - May 5 at 5:52 PM
	Immunomedics, Seattle Genetics Scrap License Deal finance.yahoo.com - May 5 at 5:52 PM
	Why Immunomedics, Inc. Rocketed Today www.fool.com - May 5 at 2:53 PM
	Immunomedics, Inc. (IMMU) Stock Rating Upgraded by Wells Fargo & Co www.americanbankingnews.com - May 5 at 12:34 PM
	Immunomedics (IMMU) Earning Favorable News Coverage, Analysis Shows www.americanbankingnews.com - May 3 at 12:20 AM
	Immunomedics (IMMU) Receiving Somewhat Favorable News Coverage, Analysis Shows www.americanbankingnews.com - April 28 at 4:44 PM
	Immunomedics, Inc. (IMMU) Short Interest Down 4.5% in April www.americanbankingnews.com - April 28 at 7:12 AM
	Somewhat Favorable News Coverage Likely to Impact Immunomedics (IMMU) Stock Price www.americanbankingnews.com - April 25 at 9:06 PM
	Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : April 25, 2017 finance.yahoo.com - April 25 at 5:22 PM
	Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017 finance.yahoo.com - April 24 at 9:12 AM
	Why Immunomedics, Inc. Got Hammered Today - Motley Fool www.fool.com - April 22 at 8:10 AM
	Somewhat Positive News Coverage Very Likely to Impact Immunomedics (IMMU) Stock Price www.americanbankingnews.com - April 21 at 9:57 PM
	Jefferies Group LLC Analysts Give Immunomedics, Inc. (IMMU) a $8.00 Price Target www.americanbankingnews.com - April 21 at 4:23 PM
	Immunomedics (IMMU) Receives Daily Media Sentiment Score of 0.25 www.americanbankingnews.com - April 18 at 1:58 PM
	Somewhat Positive News Coverage Very Likely to Effect Immunomedics (IMMU) Stock Price www.americanbankingnews.com - April 15 at 2:33 PM
	Immunomedics, Inc. (IMMU) Short Interest Up 12.2% in March www.americanbankingnews.com - April 13 at 7:30 AM
	Battle in the Boardroom: What's Next for Immunomedics finance.yahoo.com - April 7 at 10:25 AM
	Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression finance.yahoo.com - April 7 at 10:25 AM
	Biotech Movers: Paratek Spikes 34% finance.yahoo.com - April 7 at 10:25 AM
	Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan finance.yahoo.com - April 7 at 10:25 AM
	Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy finance.yahoo.com - April 7 at 10:25 AM
	Battle in the Boardroom: What's Next for Immunomedics www.fool.com - March 28 at 2:43 PM
	Short Interest in Immunomedics, Inc. (IMMU) Expands By 8.6% www.americanbankingnews.com - March 26 at 7:26 AM
	Form 3 IMMUNOMEDICS INC For: Mar 13 Filed by: Aghazadeh Behzad - StreetInsider.com www.streetinsider.com - March 24 at 10:56 PM
	Form 3 IMMUNOMEDICS INC For: Mar 13 Filed by: Islam Khalid - StreetInsider.com www.streetinsider.com - March 24 at 10:56 PM
	IMMUNOMEDICS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders biz.yahoo.com - March 16 at 4:32 PM
	Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment … finance.yahoo.com - March 15 at 11:11 PM
	Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer us.rd.yahoo.com - March 15 at 11:11 PM
	Biotech Premarket Movers: Arena, Immunomedics, Aralez www.thestreet.com - March 15 at 6:09 PM
	Markets Rally Late to Close in the Green: Today's Research Reports on Immunomedics and VIVUS us.rd.yahoo.com - March 10 at 7:07 PM
	Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN) us.rd.yahoo.com - March 10 at 7:07 PM
	IMMUNOMEDICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders us.rd.yahoo.com - March 9 at 9:01 PM